Mettler Toledo vs CoStar Group
This page compares Mettler Toledo and CoStar Group, examining their business models, financial performance, and market context in a neutral, accessible way. It presents factual, verifiable information without hype or promotion, to help readers understand how the two companies differ. Educational content, not financial advice.
This page compares Mettler Toledo and CoStar Group, examining their business models, financial performance, and market context in a neutral, accessible way. It presents factual, verifiable information...
Why It's Moving
Mettler‑Toledo rallies after solid Q3 results and bigger buyback authorization; guidance tempered by logistics headwinds
- Earnings beat: Mettler‑Toledo reported Q3 adjusted EPS of $11.15, above consensus, and reported sales of $1.03 billion, signaling continued demand that lifted margins year‑over‑year after a period of softness in earlier quarters.[2][1]
- Larger buyback authorization: The board authorized an additional $2.75 billion for share repurchases, boosting capital-return capacity and supporting per‑share metrics despite modest top‑line growth; roughly $1.1 billion remained under the prior program at announcement time.[1]
- Cautious guidance and headwinds: Management set Q4 local‑currency sales growth around +3% and issued FY EPS ranges that incorporate tariff and shipping‑delay pressures, implying the beat reflects operational strength but that supply‑chain and macro headwinds could constrain near‑term revenue momentum.[1][2]
CoStar Group's shares dip amid share price weakness, but analysts spotlight undervaluation and robust growth ahead.
- Quantum Capital Management sold 23.5% of its CSGP stake in Q2, part of ongoing institutional adjustments, while smaller funds initiated positions.
- Recent analysis pegs CSGP as 26% undervalued at $68 closing price versus $91.94 fair value, banking on 16.9% annual revenue growth and margins surging to 18.6% in three years via Homes.com expansion.
- November reports show strengthening national home price appreciation and multifamily rent growth, bolstering CoStar's core data services amid a softening stock performance.
Mettler‑Toledo rallies after solid Q3 results and bigger buyback authorization; guidance tempered by logistics headwinds
- Earnings beat: Mettler‑Toledo reported Q3 adjusted EPS of $11.15, above consensus, and reported sales of $1.03 billion, signaling continued demand that lifted margins year‑over‑year after a period of softness in earlier quarters.[2][1]
- Larger buyback authorization: The board authorized an additional $2.75 billion for share repurchases, boosting capital-return capacity and supporting per‑share metrics despite modest top‑line growth; roughly $1.1 billion remained under the prior program at announcement time.[1]
- Cautious guidance and headwinds: Management set Q4 local‑currency sales growth around +3% and issued FY EPS ranges that incorporate tariff and shipping‑delay pressures, implying the beat reflects operational strength but that supply‑chain and macro headwinds could constrain near‑term revenue momentum.[1][2]
CoStar Group's shares dip amid share price weakness, but analysts spotlight undervaluation and robust growth ahead.
- Quantum Capital Management sold 23.5% of its CSGP stake in Q2, part of ongoing institutional adjustments, while smaller funds initiated positions.
- Recent analysis pegs CSGP as 26% undervalued at $68 closing price versus $91.94 fair value, banking on 16.9% annual revenue growth and margins surging to 18.6% in three years via Homes.com expansion.
- November reports show strengthening national home price appreciation and multifamily rent growth, bolstering CoStar's core data services amid a softening stock performance.
Which Baskets Do They Appear In?
Pharma Onshoring Boom: Investment Risk Considerations
AstraZeneca is building a major new manufacturing plant in the U.S., responding to policy pressures for domestic production. This signals a broader trend of onshoring pharmaceutical manufacturing, creating opportunities for companies that build and equip these advanced facilities.
Published: October 10, 2025
Explore BasketProductivity Plays For A Cautious Economy
Recent data shows U.S. jobless claims are falling, but overall hiring remains slow, pointing to a cautious "no hire/no fire" economy. This creates a potential investment opportunity in companies focused on automation and productivity solutions, which help businesses grow without expanding their workforce.
Published: August 29, 2025
Explore BasketPharma's American Reshoring Wave
AstraZeneca is investing $50 billion to expand its U.S. manufacturing, partly in response to trade tariffs. This move could spark a wave of similar onshoring efforts, creating opportunities for companies that build, equip, and supply the growing domestic biopharmaceutical industry.
Published: July 23, 2025
Explore BasketWhich Baskets Do They Appear In?
Pharma Onshoring Boom: Investment Risk Considerations
AstraZeneca is building a major new manufacturing plant in the U.S., responding to policy pressures for domestic production. This signals a broader trend of onshoring pharmaceutical manufacturing, creating opportunities for companies that build and equip these advanced facilities.
Published: October 10, 2025
Explore BasketProductivity Plays For A Cautious Economy
Recent data shows U.S. jobless claims are falling, but overall hiring remains slow, pointing to a cautious "no hire/no fire" economy. This creates a potential investment opportunity in companies focused on automation and productivity solutions, which help businesses grow without expanding their workforce.
Published: August 29, 2025
Explore BasketPharma's American Reshoring Wave
AstraZeneca is investing $50 billion to expand its U.S. manufacturing, partly in response to trade tariffs. This move could spark a wave of similar onshoring efforts, creating opportunities for companies that build, equip, and supply the growing domestic biopharmaceutical industry.
Published: July 23, 2025
Explore BasketInvestment Analysis
Pros
- Mettler-Toledo benefits from strong global demand for precision laboratory instruments, supporting consistent revenue growth.
- The company maintains high profitability with net margins above 20% and efficient capital allocation.
- Mettler-Toledo has a solid track record of earnings growth, recently raising its annual profit forecast due to robust instrument demand.
Considerations
- Mettler-Toledo trades at a high valuation multiple, with a price-to-sales ratio above 7 and a premium to fair value estimates.
- Revenue growth has slowed in recent quarters, with year-on-year increases below 4% in the latest reporting period.
- The company has a negative debt-to-equity ratio, indicating complex capital structure and potential financial leverage risks.
CoStar Group
CSGP
Pros
- CoStar Group dominates the commercial real estate information and analytics market, benefiting from high barriers to entry.
- The company consistently generates strong free cash flow and maintains a high return on invested capital.
- CoStar Group has a history of strategic acquisitions that expand its data coverage and market reach.
Considerations
- CoStar Group's valuation is elevated, with a price-to-sales ratio significantly above industry averages.
- The business is sensitive to commercial real estate market cycles, which can impact subscription demand and pricing power.
- Recent regulatory scrutiny and legal challenges around data licensing could pose operational and reputational risks.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Comparisons
Mettler Toledo vs Vodafone
Mettler Toledo vs Vodafone
Mettler Toledo vs Teradyne
Mettler Toledo vs Teradyne: Stock comparison
Mettler Toledo vs Wipro
Mettler Toledo vs Wipro: stock comparison